Seeking Alpha

Relypsa up in debut, but off highs

  • Relypsa (RLYP +8.5%) opens at $12.47, or around 13% above where the IPO priced.
  • The company is developing patiromer for the treatment of hyperkalemia.
  • Earlier this month, RLYP reported more data to support significant top-line efficacy results from a two-part clinical trial.
  • The company notes that it has "global royalty-free commercialization rights to patiromer, which has intellectual property protection in the U.S. until at least 2030."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: